Endoceuticsä is a private pharmaceutical company operating in the field of women’s health and hormone-sensitive cancer prevention and treatment. Following approval by the FDA of Intrarosaä in November 2016, for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause, Endoceuticsä focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, including hot flushes, osteoporosis, muscle loss and type 2 diabetes. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceuticsä has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. Endoceuticsä has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.